We present a patient with CLL who achieved remission following allogeneic BMT and donor lymphocyte infusion, but 1.5 years later developed clonally identical Hodgkin's disease.
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In 2000, a 50-year-old woman was diagnosed with Rai Stage I CLL with diffuse lymphadenopathy and WBC of 21 000/mL. Translocation t(7;18) (q32;q11.2) was noted in 2 of 20 BM metaphases. When she experienced rapid lymph node progression 2 years later, she was treated with chlorambucil with no response. Partial response followed six cycles of fludarabine, cyclophosphamide and rituximab. In March 2003, she received a right breast lumpectomy and radiation for ductal carcinoma in situ. In 2004, she received six cycles of alemtuzumab (30 mcg subq tiw) with complete clinical response until CLL progressed with hepatosplenomegaly, fever, night sweats, 75 lb weight loss and hypercalcemia. BM showed 5% infiltration with small lymphocytes staining positive for CD5 and CD23 (Figure 1a-c) . Heavy-chain IgG hypermutation analysis was unmutated, predicting poor outcome. She received salvage chemotherapy with dramatic clinical improvement and resolution of fever and night sweats, but splenomegaly and diffuse lymphadenopathy persisted.
Five years after diagnosis, she underwent reduced intensity conditioning with TLI and anti-thymoglobulin, followed by allogeneic hematopoietic cell transplant (allo-HCT) from an unrelated 21-year-old female 10/10 HLAidentical donor. 1 Four doses of rituximab (anti-CD20) followed at 56-77 days after HCT on a GVHD prevention protocol. By 90 days after transplant, she achieved 100% donor CD3 T-cell chimerism (blue; Figure 1g ) and CD19 B-cell chimerism. She obtained molecular remission with no detectable CLL by allele-specific quantitative PCR assay (V H IgG assay (red)). Her CD56 NK cell and CD15 myeloid chimerism remained mixed, with a maximum donor contribution of 90% (black) and 76%, respectively. CLL was redetected by allele-specific quantitative PCR 180 days post-HCT. New hypermetabolic lymph nodes were detected by PET-CT scan (Figure 1h ). Figure 1g shows CLL expansion as donor CD3 T cell and CD56 NK-cell chimerism fell to 30% off immune-suppressive medications. Unmanipulated donor lymphocyte infusion dosed 3 Â 10 7 CD3 cells/kg at 270 days post-transplant converted her to full donor T-and NK-cell chimerism. By 90 days after donor lymphocyte infusion, she reachieved CR by allelespecific quantitative PCR and PET-CT scan (Figures 1g  and i) . She concurrently developed skin and liver GVHD, which was effectively treated with 1 mg/kg prednisone.
The patient was asymptomatic 1.5 years after transplant when surveillance PET-CT scan showed widespread lymphadenopathy, despite there being no detectable CLL using allele-specific quantitative PCR assay, BM biopsy or flow cytometry. Surprisingly, cervical lymph node biopsy showed classical Hodgkin's disease (HD) with Hodgkin Reed-Sternberg-like cells expressing CD30, CD15 and Pax5 (Figures 1d-f) . Hodgkin Reed-Sternberglike cells were in a histiocyte-rich, lymphocyte-depleted background and EBV was not detected by in situ hybridization. Cytogenetic studies were not obtained. The absence of CLL cells was confirmed by immunostaining and by flow cytometry for CD5 and CD23. However, the original CLL allele-specific V H IgH sequence amplified from the lymph node sample (784 658 clonal IgH/mg DNA) and from laser captured Hodgkin Reed-Sternberg-like cells, strongly supporting a clonal relationship between the original CLL and the newly detected HD. Despite chemotherapy treatment with adriamycin, VCR and dacarbazine, the patient continued to progress. Her PET-CT scan showed hypermetabolic activity in cervical, mediastinal, retroperitoneal and pelvic lymph nodes with skeletal lesions. She expired on 4 November 2008.
Although Hodgkin's disease coexisting with CLL cells has been previously reported, [2] [3] [4] [5] this is the first report of Hodgkin's disease being clonally related to CLL following remission of CLL after HCT. We offer several explanations for the clonal relationship between this patient's CLL B cells and Hodgkin Reed-Sternberg-like cells. We favor the explanation that a cancer stem cell may exist that gives rise to CLL and later to Hodgkin Reed-Sternberg cells sharing the same V H IgG sequence following remission of CLL. This cell would be long-lived, persisting through the 1.5 years of molecular remission. Alternatively, the cell that gives rise to both cancers may be a 'normal' memory B cell that bears the same heavy chain immunoglobulin gene rearrangement shared by CLL and HD. We hypothesize that this cell may share a transcriptome with normal memory B cells and long-term hematopoietic stem cells. 6 Another possibility is that a non-cancer stem cell CLL clone could have given rise to HD. This would imply that CLL cells persisted for 1.5 years below the technical limit of detection of our molecular assay. The absence of EBV involvement 2,7 makes this less likely, but conceivably other inciting factors could have triggered this transformation. Improvements in our understanding of normal B-cell development and cancer stem cells in lymphoid malignancies can lead to therapeutic advances to directly target the malignant cell of origin or target them in combination with HCT. 8 
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